ReviewPharmaceuticals (Basel, Switzerland)2024
A Comprehensive Review of Silver and Gold Nanoparticles as Effective Antibacterial Agents.
Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Fluorescent Biofunctionalized Silver and Gold Nanoparticles: Bright Tools for Bioimaging Applications.ACS omega · 2026Article
- Fungal-Based Biogenic Silver Nanoparticles: Synthesis, Mathematical Modeling and Application.Molecules (Basel, Switzerland) · 2026Article
- Microbial Synthesis of Precious Metal Nanoparticles and Their Applications: A Review.Microorganisms · 2026Review
- Silver-based N-heterocyclic carbene (NHC) complexes as emerging strategies against antimicrobial resistance.Archives of microbiology · 2026Review
- Tuning Anticancer Activity and Antimicrobial Response of ZnO Nanoparticles Through Halogenosilane Surface Modification.International journal of molecular sciences · 2026Article
- Green mycosynthesis of small-sized silver nanoparticles (ss-AgNPs) from endophytic Fusarium solani and their multi-target biomedical profiles.Scientific reports · 2026Article
- Crosslinked-AuNPs@CD-MOF Incorporated into PLA-Zein Composite Film with Humidity-Responsive Antimicrobial Release forFoods (Basel, Switzerland) · 2026Article
- Article
- Cyclic Olefin Copolymer with a Noble Metal Nanostructures as an Antibacterial Material.International journal of molecular sciences · 2026Article
- Multidrug Resistance and Adaptive Response to Silver and Gold Nanoparticles in Methicillin-ResistantPathogens (Basel, Switzerland) · 2026Article
- Biosynthesis and Characterization ofNanomaterials (Basel, Switzerland) · 2026Article
- Biogenesis ofInternational journal of molecular sciences · 2026Article
- Equal nano-characteristics, unequal harm: the chemical composition of noble metal nanoparticles as the main factor of cytotoxicity.Frontiers in toxicology · 2026Article
- Biogenic Silver-Selenium nanocomposite with anticancer activity and potent efficacy against vancomycin-resistant Staphylococcus aureus.PloS one · 2026Article
- Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026Review
- Sustainable nanomedicine:green synthesis of functional nanomaterials and its applications.Frontiers in chemistry · 2026Review
- Environmental applications of silver nanoparticles: state-of-the-art review and emerging trends.Beilstein journal of nanotechnology · 2026Review
- Harnessing biogenic nanoparticles for combating antibiotic resistance: green synthesis, mechanistic insights, and biotechnological applications.Frontiers in bioengineering and biotechnology · 2026Review
- Biosynthesis of silver and gold nanoparticles using cyanobacteria, their pharmaceutical and industrial applications.RSC advances · 2025Review
- Bioengineered hollow nanoflowers to synergistically modulate inflammation, angiogenesis and osteogenesis for enhancing repair of bone defects.Journal of nanobiotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing threat from antibiotic-resistant bacteria has necessitated the development of novel methods to counter bacterial infections. In this context, the application of metallic nanoparticles (NPs), especially gold (Au) and silver (Ag), has emerged as a promising strategy due to their remarkable antibacterial properties. This review examines research published between 2006 and 2023, focusing on leading journals in nanotechnology, materials science, and biomedical research. The primary applications explored are the efficacy of Ag and Au NPs as antibacterial agents, their synthesis methods, morphological properties, and mechanisms of action. An extensive review of the literature on NPs synthesis, morphology, minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and effectiveness against various Gram(+/-) bacteria confirms the antibacterial efficacy of Au and Ag NPs. The synthesis methods and characteristics of NPs, such as size, shape, and surface charge, are crucial in determining their antibacterial activity, as these factors influence their interactions with bacterial cells. Furthermore, this review underscores the urgent necessity of standardizing synthesis techniques, MICs, and reporting protocols to enhance the comparability and reproducibility of future studies. Standardization is essential for ensuring the reliability of research findings and accelerating the clinical application of NP-based antimicrobial approaches. This review aims to propel NP-based antimicrobial strategies by elucidating the properties that enhance the antibacterial activity of Ag and Au NPs. By highlighting their inhibitory effects against various bacterial strains and relatively low cytotoxicity, this work positions Ag and Au NPs as promising materials for developing antibacterial agents, making a significant contribution to global efforts to combat antibiotic-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.